sensydia_back_banner.jpg

COVID-19 highlights the acute need for non-invasive, point-of-care, remote monitoring

hemodynamic measurement solutions. Find out how CPS meets the need.

Sensydia in the news

January 19, 2022

Sensydia receives FDA breakthrough device designation for cps non-invasive cardiac monitoring device

Sensydia, an innovator in rapid, non-invasive measurement of critical cardiac function, today announced that its Cardiac Performance System (CPS) has been granted Breakthrough Device Designation by the United States Food and Drug Administration (FDA). As part of this Breakthrough Device Designation, the FDA will work closely with Sensydia to expedite the development of CPS and prioritize the review of subsequent regulatory submissions.